
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioRestorative Gets FDA Clearance for BRTX-100 Phase 2 Trial
Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic cervical discogenic pain.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 27, 2025
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioRestorative Gets FDA Fast Track for BRTX-100 in Lumbar Disc Disease
Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 20, 2025
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioRestorative Enhances Metabolic Program with Exosome-Based Biologic Targeting Obesity
Details : Company is developing a novel exosome-based biologic program for the treatment of obesity and aims to initiate first-in-human clinical studies before the end of the year.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 08, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears Phase 2 BRTX-100 Clinical Study Protocol Amendment
Details : BRTX-100 a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. It is designed to offer a non-surgical treatment for chronic lumbar disc diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Galen Patient Recruitment
Deal Size : Undisclosed
Deal Type : Partnership
BioRestorative Therapies Partners with Galen to Accelerate Enrollment in BRTX-100 Trial
Details : The partnership aims to accelerate the completion of patient enrollment in the ongoing Phase 2 study of BioRestorative's primary clinical candidate, BRTX-100, for chronic lumbar disc disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 08, 2024
Lead Product(s) : BRTX-100
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Galen Patient Recruitment
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Titan Partners Group LLC
Deal Size : $2.1 million
Deal Type : Public Offering
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
Details : The Company intends to use the proceeds for its clinical trials with respect to its lead cell therapy candidate, BRTX-100, intended for the treatment of chronic lumbar disc disease, and for pre-clinical research and development with respect to its metabo...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 11, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Titan Partners Group LLC
Deal Size : $2.1 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 07, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRTX-100 contains patient’s bone marrow autologous cultured mesenchymal stem cells. It is a novel cell-based therapeutic, engineered to target areas of the body that have little blood flow. It is currently being evaluated for chronic lumbar disc diseas...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : BRTX-100
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
